Samsung Medical Center-Lymphoma Cohort Study-II (SMC-LCS-II)
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.
Full description
Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess factors which may affect the treatment outcome and the risk of treatment-related morbidity.
1.Biologic factors associated with the aggressiveness of lymphoma
- molecular markers in serum, cytogenetic markers 2.Factors associated with the risk of treatment-related morbidity
- comorbidity, nutrition status, performance status, quality of life at diagnosis
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients who were diagnosed as lymphoma
- Over 19 years old
- Patients who agreed the enrollment of study
- Informed consent for sampling
Exclusion criteria
•Patients who do not want to join the study
Trial design
1,358 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal